Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Completed 59Terminated 16Unknown 7Active not recruiting 6Withdrawn 2

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 2Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Recurrence 2Leukemia 2Carcinoma, Renal Cell 2Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Neoplasm, Residual 1Melanoma 1Kidney Neoplasms 1Graft vs Host Disease 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × Interferon alpha-2 × Clear all
NCT04072263 2021-04-01

OVACURE

Leiden University Medical Center

Phase 1/2 Unknown
12 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT02185261 2018-06-07

Interferon α for the Therapy of Minimal Residual Disease

Peking University People's Hospital

Phase NA Unknown
81 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Recurrence, Neoplasm, Residual

NCT02568241 2016-09-29

IDPR-HSCT

Peking University People's Hospital

Phase 1/2 Unknown
42 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

NCT01729663 2015-09-02

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

Laboratorio Pablo Cassará S.R.L.

Phase 2/3 Unknown
108 enrolled
Dermatologic

Melanoma

NCT01274273 2014-12-02

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

University of Aarhus

Phase 2 Unknown
118 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00873236 2013-08-12

MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
30 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00178763 2011-03-03

FR-WB-TT

The University of Texas Health Science Center, Houston

Phase 2 Unknown
36 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡